(Total Views: 397)
Posted On: 11/01/2019 3:11:13 PM
Post# of 148908
Re: BlackDoggie #10387
It would make sense to have the same company commercialize both Combo and Mono (more so it the deal is 50% royalties). Salesforce and clients will be familiar with the product making it more efficient to phase-in from Combo to Mono if necessary, also better drug understanding.
The BIG question is: who ???
The organization of the partner will be fundamental on the royalties (as they come from sales) bottom line.)
The largest the company the better (large as far as sales force, market penetration, geographical presence, scalability potential and relevant expertise).
I thought that Syneos could fit the bill well but apparently this is not the case …
But … Who ??? . Does anybody has experience/information in pharma commercialization companies (apparently is not another pharma as NP mentioned clearly commercialization). Any ideas for sake of conversation ?
The BIG question is: who ???
The organization of the partner will be fundamental on the royalties (as they come from sales) bottom line.)
The largest the company the better (large as far as sales force, market penetration, geographical presence, scalability potential and relevant expertise).
I thought that Syneos could fit the bill well but apparently this is not the case …
But … Who ??? . Does anybody has experience/information in pharma commercialization companies (apparently is not another pharma as NP mentioned clearly commercialization). Any ideas for sake of conversation ?
(2)
(0)Scroll down for more posts ▼
